Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Evaxion Biotech ( (EVAX) ) is now available.
On May 27, 2025, Evaxion A/S announced a business update and its first quarter 2025 financial results, highlighting significant progress in its vaccine development programs. The company reported advancements in its lead asset, EVX-01, with positive data from its phase 2 trial showing an 80% tumor-specific immune response rate. Additionally, Evaxion is optimizing its AI-Immunology™ platform and expanding its R&D pipeline with new vaccine candidates, while maintaining a strong financial position with cash reserves sufficient until mid-2026. The company continues to focus on strategic partnerships and business development, despite challenges in the financial markets.
The most recent analyst rating on (EVAX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
Evaxion Biotech’s overall stock score reflects significant financial challenges despite strong revenue growth and positive strategic partnerships. While there is optimism from recent clinical successes and strategic partnerships, the persistent net losses, reliance on debt, and negative cash flow are critical concerns impacting the stock’s attractiveness. Technical indicators also suggest some caution.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion A/S is a clinical-stage TechBio company based in Denmark, specializing in the development of AI-Immunology™ powered vaccines. The company focuses on creating innovative vaccines for cancer and infectious diseases, leveraging artificial intelligence to enhance immunological responses.
Average Trading Volume: 70,692
Technical Sentiment Signal: Sell
Current Market Cap: $11.88M
For an in-depth examination of EVAX stock, go to TipRanks’ Stock Analysis page.